C
Cleveland BioLabs
Focuses on developing therapies for cancer, inflammatory, autoimmune, and infectious diseases
About Cleveland BioLabs
Founded in June 2003 by Andrei V. Gudkov and Yakov Kogan, Cleveland BioLabs operated as a clinical-stage biopharmaceutical company headquartered in Buffalo, New York. The company focused on developing novel approaches to activate the immune system, with a primary concentration on oncology and the development of orphan drugs. Its business model revolved around the research, development, and eventual commercialization of proprietary products designed to treat cancer and mitigate the toxic effects of radiation and chemotherapy.
The company's core technology was a proprietary platform of Toll-like immune receptor (TLR) activators. Its flagship product candidate was Entolimod (CBLB502), a derivative of salmonella flagellin that acts as an agonist for Toll-like receptor 5 (TLR5). Entolimod was developed for a dual-use market: as a medical countermeasure to prevent death from acute radiation syndrome (ARS) and as an immunotherapy for oncology. For the ARS indication, the drug received both Fast Track and Orphan Drug status from the U.S. Food and Drug Administration. In oncology, preclinical studies showed Entolimod could suppress the growth of certain tumors and act as a supportive care agent when combined with radiation treatment. The company's pipeline also included Mobilan, a gene therapy agent, and CBL0137, a small molecule for cancer treatment.
Throughout its history, Cleveland BioLabs established strategic partnerships with institutions like the Cleveland Clinic and Roswell Park Cancer Institute. It also engaged in joint ventures, such as Incuron, LLC, and Panacela Labs, Inc., to advance its pipeline. A significant corporate milestone occurred in October 2020, when Cleveland BioLabs entered into a definitive merger agreement with Cytocom Inc. This all-stock, reverse merger transaction was completed on July 27, 2021, with the combined entity operating under the name Cytocom, Inc. The merger was positioned as a transformative event, creating a combined company with a broad pipeline focused on immune-modulating therapies for cancer, autoimmune diseases, and inflammatory conditions.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2003
- Headquarters
- Buffalo, United States
- Listing
- IPO 2006
- Employees
- 22
- Open positions
- None listed
- Dealroom signal
- 49.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, Cancer Care Companion, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| MERGER✓Other financing | Jul 2021 | — | — | Statera BioPharma | ↗ |
| POST IPO EQUITY✓Other financing | Feb 2021 | $14M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Cleveland BioLabs is 370 monthly website visits, up 1133.3% over the last three months. Cleveland BioLabs's team declined 4.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Cleveland BioLabs in the Buffalo ecosystem
The Cleveland BioLabs office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
Hercules Capital- DDDavid Davidovich
- NINorma Investment
Other known investors3 additional known investors
Cleveland Clinic
Statera BioPharma
Small Business Innovation Research
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cleveland BioLabs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cleveland BioLabs’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









